Cambridge, UK, 28 July 2026 - One Nucleus expands its portfolio of member benefits through o2h co-discovery bringing discounted exclusive access for eligible One Nucleus members to specialist in-vitro ADME and DMPK services designed to support early-stage drug discovery.
The initiative has been developed in response to the challenges many emerging biotech companies face in today's funding environment, where access to high-quality preclinical data is increasingly important for understanding compound behaviour, progressing programmes, raising investment and making confident business…
Pioneer Group and Oxford Properties have announced that Syncona Investment Management Ltd (SIML), a leading life science investment manager, is moving into Victoria House, a leading hub for life sciences in London.
Developed by Pioneer Group and Oxford Properties, Victoria House in Bloomsbury, London continues to build one of London’s most inspiring life science communities, where an ever-growing number of pioneering organisations are driving innovation across science, biopharmaceuticals, gene therapies, synthetic biology and AI.
SIML is the investment manager for Syncona Limited, a FTSE 250…
The One Nucleus Awards has been integrated into the Genesis Conference, to recognise outstanding achievements across our ecosystem. All shortlisted companies will receive a free delegate pass and will be invited to pitch at the company showcase, plus having the opportunity to network with over 400 delegates.
Deadline Approaching: Entries close on 17 September, enter here with our easy entry form.
All welcome to enter or nominate - you don’t need to be a One Nucleus member nor a UK company
Celebrate in person at Genesis!
If you are not shortlisted, nobody knows you entered, so there…
Pilot study to develop prototype agentic AI sub-system for initial validation screening of targets identified using AI predictive genomics platform, Nomaly
Funding provided jointly by Innovate UK and Empirical Ventures through Innovate UK Growth Catalyst – Investor Partnership grant programme
Cambridge, UK, 8 September 2026: OutSee, a genomics and drug discovery company pioneering a unique AI-based predictive approach to uncover new drug targets, today announced it has been awarded funding through Innovate UK’s Investor Partnership Grant, jointly provided by Innovate UK and Empirical…
StemFit Basic04CT from Amsbio is an animal-origin-free, defined, ready-to-use medium designed to support seamless human pluripotent stem cell culture—from iPSC establishment through expansion, and from research to clinical manufacturing. Its simplified one-bottle formulation streamlines process development while reducing workflow complexity and contamination risk.
In rigorous testing - StemFit Basic04CT demonstrated improved workflow efficiency, enhanced ease of adoption and the lowest cost per well compared to other popular xeno-free stem cell culture products.
Dr Philipp…
Community café and flexible meeting space welcomes local groups, residents and businesses alike
Glasgow, 7 September, 2026
Since opening earlier this year, Glasgow's pioneering Health Innovation Hub (HiH) has both been home to world-class life science innovation and opened its doors to the local community. In recent months representatives from over 20 different organisations and local groups have utilised the community cafe space.
Officially opened in March 2026, the purpose-built facility has become home to pioneering organisations including Chemify, the HealthTech Innovation &…
9am BST, Stevenage, 7 Sep 2026
The Board of SBC is delighted to announce the promotion of Andrew Waters from his current position of Chief Financial Officer & Interim CEO to the position of Chief Executive Officer.
Andrew has a First Class Physics degree from Imperial College, is an FCA Chartered Accountant and has worked almost his whole career within the Life Sciences industry. After 4 years at PwC London, Andrew spent 16 years at GSK in a number of positions across R&D and the commercial business including time working overseas in US, Denmark and Netherlands. …
Helping high-throughput laboratories increase multiplexing capacity and maximise sequencing throughput without changing established workflows
Oxford, UK, September 2026.
OGT, a leading global provider of genomic research and diagnostic solutions, today announced the expansion of its SureSeq™ Universal NGS Unique Dual Index (UDI) range, enabling laboratories to multiplex up to 384 uniquely indexed samples in a single sequencing run. Compatible with existing SureSeq™ workflows and software, expanded UDI capabilities provide a straightforward path for laboratories looking to scale throughput…
LONDON, UK – September 3, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully led a search assignment for NRG Therapeutics Ltd. ("NRG") and is pleased to announce the placement of Claus Sundgreen, M.D. as Chief Medical Officer (CMO).NRG Therapeutics is a clinical-stage neuroscience company developing novel disease-modifying therapeutics that restore mitochondrial health in neurodegenerative diseases. Its lead clinical asset, NRG5051, is a first-in-class, orally bioavailable and CNS-penetrant next-…
Investment and expert support will help accelerate the development of new treatments for a range of autoimmune, inflammatory, and age-related diseases
Two UK biotechs developing novel approaches to treating diseases such as psoriasis and Parkinson’s have secured investment and strategic support from Medicines Discovery Catapult (MDC) to accelerate their progress.
Flip Therapeutics and Nascent Therapeutics will each receive £500,000 in funding made available by Innovate UK as part of a scheme that enabled Catapults to invest in high-potential companies.
Alongside the investment, MDC, which…